WASHINGTON, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-39100 ____________________________________________ Progyny, Inc. (Exact name of registrant as specified in its charter) ________________________ ...

Progyny, Inc. (NASDAQ:PGNY) Q1 2023 Earnings Conference Call May 8, 2023 4:45 PM ET Company Participants James Hart - Investor Relations Pete Anevski - Chief Executive Officer Michael Sturmer - President Mark Livingston - Chief Financial Officer Conference Call Participants Anne Samuel - JPMorgan Scott Schoenhaus - KeyBanc Sarah James - Cantor Fitzgerald Eduardo Ron - Truist Securities Anna Kruszenski - SVB Securities Michael Weisberg - Crestwood Capital Operator Good day, ladies and gentlemen and welcome t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39100 Progyny, Inc. (Exact name of registrant as specified in its charter) ...

Progyny, Inc. (NASDAQ:PGNY) Q4 2022 Earnings Conference Call February 27, 2023 4:45 PM ET Company Participants James Hart - Vice President of Investor Relations Peter Anevski - Chief Executive Officer Mark Livingston - Chief Financial Officer Michael Sturmer - President Conference Call Participants Michael Cherny - Bank of America Jailendra Singh - Truist Securities Scott Schoenhaus - KeyBanc Stephanie Davis - SVB Securities Operator Good day, ladies and gentlemen and welcome to the Progyny Inc. Fourth Quar ...

Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Com ...

Progyny, Inc. (NASDAQ:PGNY) Q3 2022 Earnings Conference Call November 3, 2022 4:45 PM ET Company Participants James Hart - VP, IR Peter Anevski - CEO Mark Livingston - CFO Conference Call Participants Anne Samuel - JPMorgan Jailendra Singh - Truist Securities Scott Schoenhaus - KeyBanc Glen Santangelo - Jefferies Sarah James - Barclays Stephanie Davis - SVB Securities Deb Weerasuriya - Berenberg Operator Good afternoon, ladies and gentlemen, and welcome to the Progyny, Inc. Third Quarter 2022 Earnings Call. ...

Progyny, Inc. (NASDAQ:PGNY) Q2 2022 Earnings Conference Call August 4, 2022 4:45 PM ET Company Participants James Hart - Vice President of Investor Relations Peter Anevski - Chief Executive Officer Michael Sturmer - President Mark Livingston - Chief Financial Officer Conference Call Participants Anne Samuel - JPMorgan Sarah James - Barclays Stephanie Davis - SVB Securities Dev Weerasuriya – Berenberg Capital Markets Operator Good afternoon, ladies and gentlemen, and welcome to today's Progyny Inc. Second Qu ...

Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commissi ...

Financial Position - The company reported cash and cash equivalents of $38.8 million and marketable securities of $66.9 million as of March 31, 2022[175]. - A hypothetical 10% change in interest rates would not result in a material impact on the company's consolidated financial statements[176]. - The company does not believe that inflation has had a material effect on its business, financial condition, or results of operations[177]. Business Operations - The ongoing COVID-19 pandemic continues to have an adverse impact on the company's business and operations[16]. - The company has a history of operating losses and may not sustain profitability in the future[16]. - The company relies on retaining existing clients and increasing service adoption to maintain its financial health[16]. - A significant portion of the company's revenue comes from its largest clients, primarily in the technology industry[16]. - The company operates in a highly regulated industry and must comply with complex legal and regulatory requirements[22]. Internal Controls - The effectiveness of the company's disclosure controls and procedures was evaluated and deemed effective at the reasonable assurance level as of March 31, 2022[179]. - There were no changes in the company's internal control over financial reporting that materially affected its financial reporting during the quarter ended March 31, 2022[180].

Progyny, Inc. (NASDAQ:PGNY) Q1 2022 Earnings Call Transcript May 5, 2022 5:00 PM ET Company Representatives Peter Anevski - Chief Executive Officer Michael Sturmer - President Mark Livingston - Chief Financial Officer James Hart - Vice President of Investor Relations Conference Call Participants Anne Samuel - JPMorgan Michael Cherny - Bank of America Sarah James - Barclays Glen Santangelo - Jefferies Stephanie Davis - SVB Securities Dev Weerasuriya - Berenberg Operator Good afternoon, ladies and gentlemen, ...